AU2001296477A1 - Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas - Google Patents
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomasInfo
- Publication number
- AU2001296477A1 AU2001296477A1 AU2001296477A AU9647701A AU2001296477A1 AU 2001296477 A1 AU2001296477 A1 AU 2001296477A1 AU 2001296477 A AU2001296477 A AU 2001296477A AU 9647701 A AU9647701 A AU 9647701A AU 2001296477 A1 AU2001296477 A1 AU 2001296477A1
- Authority
- AU
- Australia
- Prior art keywords
- cyr61
- diagnosis
- treatment
- human uterine
- uterine leiomyomas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23688700P | 2000-09-29 | 2000-09-29 | |
US60/236,887 | 2000-09-29 | ||
PCT/US2001/030783 WO2002026193A2 (en) | 2000-09-29 | 2001-09-28 | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001296477A1 true AU2001296477A1 (en) | 2002-04-08 |
Family
ID=22891403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001296477A Abandoned AU2001296477A1 (en) | 2000-09-29 | 2001-09-28 | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1322778A4 (en) |
JP (1) | JP2004509909A (en) |
AU (1) | AU2001296477A1 (en) |
CA (1) | CA2423413A1 (en) |
WO (1) | WO2002026193A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858324B2 (en) * | 2005-02-18 | 2010-12-28 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
TW201102086A (en) | 2009-06-04 | 2011-01-16 | Hoffmann La Roche | Antibodies against human CCN1 and uses thereof |
WO2011066783A1 (en) * | 2009-12-04 | 2011-06-09 | 上海市免疫学研究所 | Anti-cyr61 protein monoclonal antibodies and uses thereof |
EP3364190A1 (en) * | 2017-02-20 | 2018-08-22 | Panka Cancer Research AG | Method of detecting cancer or cancer cells |
CN108752454B (en) * | 2018-06-19 | 2021-07-20 | 中山大学孙逸仙纪念医院 | Human CYR61 protein Ser188 site phosphorylation antigen and antibody, and preparation method and application thereof |
RU2704817C1 (en) * | 2019-07-09 | 2019-10-31 | Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации | Method for predicting uterine leiomyoma size increase |
-
2001
- 2001-09-28 CA CA002423413A patent/CA2423413A1/en not_active Abandoned
- 2001-09-28 AU AU2001296477A patent/AU2001296477A1/en not_active Abandoned
- 2001-09-28 WO PCT/US2001/030783 patent/WO2002026193A2/en active Application Filing
- 2001-09-28 EP EP01977351A patent/EP1322778A4/en not_active Withdrawn
- 2001-09-28 JP JP2002530024A patent/JP2004509909A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002026193A3 (en) | 2002-10-03 |
WO2002026193A9 (en) | 2003-02-20 |
JP2004509909A (en) | 2004-04-02 |
EP1322778A4 (en) | 2005-06-15 |
WO2002026193A2 (en) | 2002-04-04 |
EP1322778A2 (en) | 2003-07-02 |
CA2423413A1 (en) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001275177A1 (en) | Cardiac disease treatment and device | |
AU2001253565A1 (en) | Cardiac disease treatment and device | |
AU2001275176A1 (en) | Cardiac disease treatment and device | |
AU2001281369A1 (en) | Cardiac disease treatment and device | |
AU2001293553A1 (en) | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment | |
AU1166502A (en) | Human ect2 and methods of use | |
IL205242A0 (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
AU2001249835A1 (en) | Diagnosis and treatment of alzheimer's disease | |
AU2003243551A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
AU2002227184A1 (en) | Methods for development and use of diagnostic and therapeutic agents | |
AU2001280440A1 (en) | Treatment of human herpesviruses using hyperthermia | |
AU2001283285A1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
ZA200301204B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU8678501A (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU2002222108A1 (en) | Diagnosis and treatment of alzheimer's disease | |
AU2002220257A1 (en) | Methods of treatment involving human mda-7 | |
AU2003238242A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
AU2001296477A1 (en) | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas | |
AU3501700A (en) | Human endokine alpha and methods of use | |
AU2001253886A1 (en) | Methylxanthines in the diagnosis and treatment of autistic disorder | |
AU2001242490A1 (en) | Device for treating human and/or animal tissue | |
AU4319001A (en) | Microcompetiton and human disease | |
GB9908059D0 (en) | Diagnosis and treatment of diseases | |
AU2001253024A1 (en) | Diagnosis and treatment of gastrointestinal disease | |
AU2001285026A1 (en) | Methods and compositions for use in the diagnosis and treatment of chronic immune disease |